Natural lipid acts as potent anti-inflammatory

10 Jul 2018

Scientists see therapeutic potential against bacteria, viruses.

National Institutes of Health (NIH) researchers have identified a naturally occurring lipid used by a disease-causing bacterium to impair the host immune response and increase the chance of infection. Inadvertently, they also may have found a potent inflammation therapy against bacterial and viral diseases.

Natural lipid acts as potent anti-inflammatory

Lipids are known to help Francisella tularensis bacteria, the cause of tularemia, to suppress host inflammation when infecting mouse and human cells. In a new study published in the Journal of Innate Immunity, researchers from NIH’s National Institute of Allergy and Infectious Diseases found a form of the lipid phosphatidylethanoloamine, or PE, present in the bacterium. The composition of PE found in F. tularensis differs from PE found in other bacteria. In cell-culture experiments, the researchers discovered that the natural and a synthetic form of PE reduced inflammation caused by both tularemia bacteria and dengue fever virus.

Tularemia is a life-threatening disease spread to humans via contact with an infected animal or through the bite of a mosquito, tick or deer fly. Although tularemia can be successfully treated with antibiotics, it is difficult to diagnose, mainly because F. tularensis bacteria can suppress the human immune response. Dengue fever, primarily spread by Aedes aegypti mosquitoes, is rarely fatal but usually leads to a high fever, severe headache and pain throughout the body. There is no specific treatment for dengue fever.

After identifying PE as the lipid that impaired the immune response, the scientists began to consider its potential therapeutic value. Because natural F. tularensis is highly infectious and therefore challenging to work with, the group developed synthetic lipids — PE2410 and PEPC2410 — that would be much easier to study and produce. They then verified that both synthetic lipids also suppressed the immune response during infection of mouse and human cells in the laboratory.

Because several types of viral infections involve an unconstrained inflammatory response, the group tested natural and their synthetic PE in the laboratory against dengue fever virus-infected human cells. Both versions inhibited the immune response compared to the immune response seen in infected but untreated cells.

The group plans to continue exploring how F. tularensis impairs the immune response. They hope their findings will eventually lead to the development of a potent, broad-spectrum anti-inflammatory therapeutic.

Read More

Related news

Plasticell wins military contract to develop regenerative medicines for the battlefield

Plasticell wins military contract to develop regenerative medicines for the battlefield

4 Sep 2018

Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

Read more 
New biopharmaceutical testing laboratory to open in Geneva

New biopharmaceutical testing laboratory to open in Geneva

28 Aug 2018

SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.

Read more 
Exosome isolation manufacturing and characterization

Exosome isolation manufacturing and characterization

13 Aug 2018

New service to reliably and reproducibly isolate exosomes from almost any biofluid.

Read more 
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
WuXi STA and Antengene sign development and manufacturing agreement

WuXi STA and Antengene sign development and manufacturing agreement

24 Jul 2018

WuXi STA chosen for its end-to-end CMC platform for new drug development.

Read more 
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

18 Jul 2018

Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.

Read more 
New screening company exploits the latest advances in microfluidics and 3D culture

New screening company exploits the latest advances in microfluidics and 3D culture

19 Jul 2018

The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies to do 100x more testing for the same money spent as well as increasing productivity.

Read more 
Plasticell leads gene therapy manufacturing consortium

Plasticell leads gene therapy manufacturing consortium

3 Jul 2018

Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

Read more 
Follicum develops new direct-to-scalp formulation

Follicum develops new direct-to-scalp formulation

27 Jun 2018

The topical treatment for hair loss boasts a 'commercial' formulation.

Read more